GEKKOVET-OY
17.6.2021 11:34:12 CEST | Business Wire | Press release
There are hundreds of different diseases and even more symptoms that can affect pets. Even a veterinarian cannot remember all of them without help. The new GekkoCompass application, recently launched by a Finnish company, suggests the most probable diagnosis and the appropriate treatment at the touch of a button to the veterinarian.
In treating their patients, veterinarians use numerous different sources to arrive at a diagnosis. Now, however, there is no longer a need for stacks of books or confusing notes. GekkoCompass creates a list of possible diagnoses in probability order, based on the patient’s symptoms, laboratory results, and other findings. After the diagnosis is selected, the appropriate treatments are suggested to the veterinarian. GekkoCompass provides support throughout the patient's treatment chain reducing the risk of human error at all stages. It does not forget things and preconceptions will not influence the diagnoses suggested.
GekkoCompass currently includes information for internal diseases of dogs and cats. With these alone there are nearly 25,000 different disease-symptom combinations. The content will grow to embrace new animal species as well as different fields of veterinary medicine. All this information is available to all veterinarians worldwide - regardless of the level of veterinary education or the country’s resources.
Johanna Majamaa, CEO of GekkoVet Oy, states: “The main idea behind this application’s development has been the desire to promote animal welfare worldwide. With GekkoCompass, the veterinarian will find diagnoses and recommended treatments faster and with greater confidence. At the same time, information is accumulated as veterinary medicine real world data (RWD). This is the first time ever when this data is automatically structured along the patient treatment path. PetCompass, a sister product that we have just launched, arose out of this same idea, but is intended for pet owners. We thought, why not provide professional-level information to animal owners as well and facilitate the flow of information between owners and veterinarians?”
Until now, pet owners have had to look for pet health information from a variety of sources, the reliability of which varies greatly. Now up-to-date information on the pet’s condition is easily available in one place through the PetCompass mobile app.
GekkoVet Oy is working with If P&C Insurance, which offers its dog and cat insurance customers the Premium version of the PetCompass application for 3 months free of charge. “During the corona pandemic, the number of new pet owners has grown sharply. We want to help, especially, the less experienced dog and cat owners by offering peace of mind in the different everyday situations that they and their pets find themselves in. The application provides a reliable and effortless way to discover the causes of a pet's symptoms and to easily get in touch with a veterinarian (or a remote veterinarian) if this is necessary,” says Heidi Elomaa, If's veterinarian and Product Manager for Animal Insurance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005381/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
